Kai Kang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kai Kang has a total of 102 co-authors. Here are the top co-authors by number of shared publications:
- Yijun Wu
Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University
11 shared publications - You Lu
Division of Thoracic Tumor Multimodality Treatment, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
7 shared publications - Ailin Zhao
Department of Hematology, West China Hospital, Sichuan University, Chengdu, China
6 shared publications - Zhuoran Yao
Department of Radiotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, China; Division of Thoracic Tumor Multimodality Treatment, Cancer Center and Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu 610041, Sichuan, China
6 shared publications - Gabriele Niedermann
Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany
5 shared publications - Jianxin Xue
West China Hospital Sichuan University Chengdu China
5 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 7568
SBRT embedded in low-dose RT plus αPD-1 (immuno-EclipseRT, iERT) elicits CD8+ T cell immunity against bulky tumors via an IFN-I/NK/DC axis
Bulky tumors remain challenging to treat, and immune checkpoint inhibitors (ICIs), alone or combined with conventional radiotherapy (RT), yield limited efficacy. We present EclipseRT (ERT), an RT technique that delivers low-dose RT (LDRT) to the gross tumor volume (GTV) and stereotactic body RT (SBRT) to selected subvolume(s) within the GTV. Combined with ICIs (iERT), this approach achieves marked control of bulky tumors through the coordinated activity of NK and CD8⁺ T cells. Single-cell RNA sequencing and validation experiments show that the SBRT component robustly induces type I interferon (IFN-I), which activates NK cells to secrete XCL1, thereby recruiting cross-presenting XCR1⁺ dendritic cells (DCs). SBRT also promotes the release of extracellular vesicles carrying neoantigens, enhancing DC cross-presentation and CD8⁺ T-cell responses. The LDRT component further promotes NK and CD8⁺ T-cell recruitment. iERT also induces precursor exhausted CD8⁺ T cells in tumors and tumor-draining lymph nodes. Collectively, iERT activates the IFN-I/NK/DC/CD8⁺ T-cell axis, driving potent antitumor immunity against bulky tumors.
- 8 July 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1) , 7568
Open AccessSBRT embedded in low-dose RT plus αPD-1 (immuno-EclipseRT, iERT) elicits CD8+ T cell immunity against bulky tumors via an IFN-I/NK/DC axis
Bulky tumors remain challenging to treat, and immune checkpoint inhibitors (ICIs), alone or combined with conventional radiotherapy (RT), yield limited efficacy. We present EclipseRT (ERT), an RT technique that delivers low-dose RT (LDRT) to the gross tumor volume (GTV) and stereotactic body RT (SBRT) to selected subvolume(s) within the GTV. Combined with ICIs (iERT), this approach achieves marked control of bulky tumors through the coordinated activity of NK and CD8⁺ T cells. Single-cell RNA sequencing and validation experiments show that the SBRT component robustly induces type I interferon (IFN-I), which activates NK cells to secrete XCL1, thereby recruiting cross-presenting XCR1⁺ dendritic cells (DCs). SBRT also promotes the release of extracellular vesicles carrying neoantigens, enhancing DC cross-presentation and CD8⁺ T-cell responses. The LDRT component further promotes NK and CD8⁺ T-cell recruitment. iERT also induces precursor exhausted CD8⁺ T cells in tumors and tumor-draining lymph nodes. Collectively, iERT activates the IFN-I/NK/DC/CD8⁺ T-cell axis, driving potent antitumor immunity against bulky tumors.
- Open Access
- 1 May 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (5) , 102785
Cross-tissue atlas of mucosa-associated lymphoid tissue lymphomas reveals intratumoral heterogeneity and microenvironmental subtypes
- 1 May 2026
- Published by Elsevier in Cell Reports Medicine
- Vol. 7 (5) , 102785
Open AccessCross-tissue atlas of mucosa-associated lymphoid tissue lymphomas reveals intratumoral heterogeneity and microenvironmental subtypes
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients
2 figures,3 tables and 3 texts
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients
2 figures,3 tables and 3 texts
- Open Access
- 27 August 2025
- Published by Elsevier in Cell Reports Medicine
- Vol. 6 (9) , 102315
Addressing clinical needs in NSCLC immunotherapy: Mechanisms of resistance and promising combination strategies
- 27 August 2025
- Published by Elsevier in Cell Reports Medicine
- Vol. 6 (9) , 102315
Open AccessAddressing clinical needs in NSCLC immunotherapy: Mechanisms of resistance and promising combination strategies
- Open Access
- 22 November 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (1) , 1642-1645
Heterogeneity of tumor-infiltrating T cells and its impact on anti-PD-1/PD-L1 immunotherapy: insights from integrated multicancer single-cell and bulk transcriptomic analysis
An abstract is unavailable. This article is available as a PDF only.
- 22 November 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 111 (1) , 1642-1645
Open AccessHeterogeneity of tumor-infiltrating T cells and its impact on anti-PD-1/PD-L1 immunotherapy: insights from integrated multicancer single-cell and bulk transcriptomic analysis
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small-Cell Lung Cancer Patients
2 figures,3 tables and 3 texts
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small-Cell Lung Cancer Patients
2 figures,3 tables and 3 texts
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small-Cell Lung Cancer Patients
2 figures,3 tables and 3 texts
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naive Stage IV PD-L1+ Non-Small-Cell Lung Cancer Patients
2 figures,3 tables and 3 texts
- 21 June 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (1) , E1-E2
Letter to the Editor: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis
- 21 June 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (1) , E1-E2
Letter to the Editor: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis
- Open Access
- 8 May 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (8) , 5304-5305
Breast cancer in the era of generative artificial intelligence: assistant tools for clinical doctors based on ChatGPT
An abstract is unavailable. This article is available as a PDF only.
- 8 May 2024
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 110 (8) , 5304-5305
Open AccessBreast cancer in the era of generative artificial intelligence: assistant tools for clinical doctors based on ChatGPT
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 1 May 2024
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 13 (5) , 1032-1046
CDK4/6 inhibitor abemaciclib combined with low-dose radiotherapy enhances the anti-tumor immune response to PD-1 blockade by inflaming the tumor microenvironment in Rb-deficient small cell lung cancer
Background: Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have shown significant activity against several solid tumors by reducing the phosphorylation of the canonical CDK4/6 substrate retinoblastoma (Rb) protein, while the anti-tumor effect of CDK4/6 inhibitors on Rb-deficient tumors is not clear. Most small cell lung cancers (SCLCs) are Rb-deficient and show very modest response to immune checkpoint blockade (ICB) despite recent advances in the use of immunotherapy. Here, we aimed to investigate the direct effect of CDK4/6 inhibition on SCLC cells and determine its efficacy in combination therapy for SCLC. Methods: The immediate impact of CDK4/6 inhibitor abemaciclib on cell cycle, cell viability and apoptosis in four SCLC cell lines was initially checked. To explore the effect of abemaciclib on double-strand DNA (ds-DNA) damage induction and the combination impact of abemaciclib coupled with radiotherapy (RT), western blot, immunofluorescence (IF) and quantitative real-time polymerase chain reaction (qRT-PCR) were performed. An Rb-deficient immunocompetent murine SCLC model was established to evaluate efficacy of abemaciclib in combination therapy. Histological staining, flow cytometry analysis and RNA sequencing were performed to analyze alteration of infiltrating immune cells in tumor microenvironment (TME). Results: Here, we demonstrated that abemaciclib induced increased ds-DNA damage in Rb-deficient SCLC cells. Combination of abemaciclib and RT induced more cytosolic ds-DNA, and activated the STING pathway synergistically. We further showed that combining low doses of abemaciclib with low-dose RT (LDRT) plus anti-programmed cell death protein-1 (anti-PD-1) antibody substantially potentiated CD8+ T cell infiltration and significantly inhibited tumor growth and prolonged survival in an Rb-deficient immunocompetent murine SCLC model. Conclusions: Our results define previously uncertain DNA damage-inducing properties of CDK4/6 inhibitor abemaciclib in Rb-deficient SCLCs, and demonstrate that low doses of abemaciclib combined with LDRT inflame the TME and enhance the efficacy of anti-PD-1 immunotherapy in SCLC model, which represents a potential novel therapeutic strategy for SCLC.
- 1 May 2024
- Published by AME Publishing Company in Translational Lung Cancer Research
- Vol. 13 (5) , 1032-1046
Open AccessCDK4/6 inhibitor abemaciclib combined with low-dose radiotherapy enhances the anti-tumor immune response to PD-1 blockade by inflaming the tumor microenvironment in Rb-deficient small cell lung cancer
Background: Cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have shown significant activity against several solid tumors by reducing the phosphorylation of the canonical CDK4/6 substrate retinoblastoma (Rb) protein, while the anti-tumor effect of CDK4/6 inhibitors on Rb-deficient tumors is not clear. Most small cell lung cancers (SCLCs) are Rb-deficient and show very modest response to immune checkpoint blockade (ICB) despite recent advances in the use of immunotherapy. Here, we aimed to investigate the direct effect of CDK4/6 inhibition on SCLC cells and determine its efficacy in combination therapy for SCLC. Methods: The immediate impact of CDK4/6 inhibitor abemaciclib on cell cycle, cell viability and apoptosis in four SCLC cell lines was initially checked. To explore the effect of abemaciclib on double-strand DNA (ds-DNA) damage induction and the combination impact of abemaciclib coupled with radiotherapy (RT), western blot, immunofluorescence (IF) and quantitative real-time polymerase chain reaction (qRT-PCR) were performed. An Rb-deficient immunocompetent murine SCLC model was established to evaluate efficacy of abemaciclib in combination therapy. Histological staining, flow cytometry analysis and RNA sequencing were performed to analyze alteration of infiltrating immune cells in tumor microenvironment (TME). Results: Here, we demonstrated that abemaciclib induced increased ds-DNA damage in Rb-deficient SCLC cells. Combination of abemaciclib and RT induced more cytosolic ds-DNA, and activated the STING pathway synergistically. We further showed that combining low doses of abemaciclib with low-dose RT (LDRT) plus anti-programmed cell death protein-1 (anti-PD-1) antibody substantially potentiated CD8+ T cell infiltration and significantly inhibited tumor growth and prolonged survival in an Rb-deficient immunocompetent murine SCLC model. Conclusions: Our results define previously uncertain DNA damage-inducing properties of CDK4/6 inhibitor abemaciclib in Rb-deficient SCLCs, and demonstrate that low doses of abemaciclib combined with LDRT inflame the TME and enhance the efficacy of anti-PD-1 immunotherapy in SCLC model, which represents a potential novel therapeutic strategy for SCLC.